Fibrobiologics IncNASDAQ:FBLG
- LAST PRICE10.1100
- TODAY'S CHANGE (%)-1.5700 (-13.4418%)
- Bid / Lots9.7000/ 5
- Ask / Lots11.5500/ 19
- Open / Previous Close11.0600 / 11.6800
- Day Range
- 52 Week Range
- Volume100,749
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBLG |
|---|---|---|
| 09:54 ET | 5031 | 10.92 |
| 09:56 ET | 1000 | 10.76 |
| 10:01 ET | 300 | 10.925 |
| 10:03 ET | 100 | 10.825 |
| 10:06 ET | 200 | 10.76 |
| 10:08 ET | 2677 | 10.3069 |
| 10:14 ET | 200 | 10.3501 |
| 10:15 ET | 195 | 10.39 |
| 10:17 ET | 600 | 10.3901 |
| 10:19 ET | 200 | 10.42 |
| 10:21 ET | 1279 | 10.415 |
| 10:32 ET | 500 | 10.37 |
| 10:33 ET | 500 | 10.37 |
| 10:42 ET | 214 | 10.26 |
| 10:51 ET | 3000 | 10.7353 |
| 10:53 ET | 1000 | 10.505 |
| 10:57 ET | 100 | 10.2701 |
| 11:04 ET | 1909 | 10.7175 |
| 11:06 ET | 200 | 10.3501 |
| 11:09 ET | 5148 | 10.2902 |
| 11:11 ET | 100 | 10.51 |
| 11:13 ET | 101 | 10.3 |
| 11:22 ET | 100 | 10.52 |
| 11:29 ET | 100 | 10.54 |
| 11:31 ET | 112 | 10.54 |
| 11:38 ET | 100 | 10.545 |
| 11:42 ET | 2100 | 10.55 |
| 11:44 ET | 400 | 10.3101 |
| 11:45 ET | 100 | 10.55 |
| 11:49 ET | 100 | 10.6875 |
| 11:51 ET | 100 | 10.5 |
| 11:58 ET | 100 | 10.585 |
| 12:02 ET | 200 | 10.585 |
| 12:03 ET | 500 | 10.52 |
| 12:05 ET | 100 | 10.53 |
| 12:09 ET | 997 | 10.415 |
| 12:12 ET | 544 | 10.415 |
| 12:14 ET | 100 | 10.415 |
| 12:25 ET | 100 | 10.43 |
| 12:34 ET | 200 | 10.332 |
| 12:41 ET | 100 | 10.51 |
| 12:48 ET | 100 | 10.535 |
| 12:52 ET | 100 | 10.3801 |
| 12:56 ET | 402 | 10.38 |
| 12:57 ET | 300 | 10.36 |
| 12:59 ET | 100 | 10.3 |
| 01:06 ET | 1601 | 10.135 |
| 01:08 ET | 500 | 10.0602 |
| 01:10 ET | 200 | 10.1 |
| 01:12 ET | 250 | 10.1 |
| 01:14 ET | 100 | 10.1 |
| 01:15 ET | 101 | 10.1026 |
| 01:19 ET | 1343 | 10.08 |
| 01:21 ET | 3910 | 10.04 |
| 01:24 ET | 2500 | 10.0098 |
| 01:26 ET | 2524 | 9.805 |
| 01:28 ET | 2911 | 9.72 |
| 01:30 ET | 100 | 9.61 |
| 01:33 ET | 300 | 9.747 |
| 01:46 ET | 150 | 9.7001 |
| 01:50 ET | 500 | 9.9 |
| 01:51 ET | 1100 | 10.055 |
| 02:06 ET | 822 | 9.92 |
| 02:22 ET | 200 | 9.73 |
| 02:26 ET | 400 | 9.7001 |
| 02:29 ET | 500 | 9.7501 |
| 02:42 ET | 101 | 9.7501 |
| 02:44 ET | 360 | 9.7692 |
| 02:47 ET | 202 | 9.875 |
| 02:54 ET | 400 | 9.885 |
| 02:56 ET | 300 | 9.985 |
| 03:07 ET | 100 | 9.99 |
| 03:09 ET | 700 | 10 |
| 03:16 ET | 100 | 9.99 |
| 03:20 ET | 1518 | 9.82 |
| 03:21 ET | 1000 | 9.84 |
| 03:23 ET | 1900 | 9.9 |
| 03:25 ET | 5699 | 10.01 |
| 03:27 ET | 100 | 10.24 |
| 03:32 ET | 1019 | 9.92 |
| 03:34 ET | 4742 | 9.92 |
| 03:36 ET | 1852 | 10 |
| 03:38 ET | 1378 | 9.84 |
| 03:39 ET | 2800 | 9.85 |
| 03:41 ET | 6627 | 9.83 |
| 03:48 ET | 100 | 9.8801 |
| 03:54 ET | 700 | 10.075 |
| 03:57 ET | 635 | 10.01 |
| 03:59 ET | 300 | 10.11 |
Apr 25, 2024
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids, from 8:00AM ET on Thursday Apr 25, 2024 by Dow Jones
8:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 11, 2024
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office, from 9:31AM ET on Thursday Apr 11, 2024 by Dow Jones
9:31AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 4, 2024
Mar 28, 2024
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus, from 9:31AM ET on Thursday Mar 28, 2024 by Dow Jones
9:31AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Fibrobiologics Inc | 330.8M | -11.1x | --- |
Erasca Inc | 327.6M | -2.3x | --- |
Rani Therapeutics Holdings Inc | 336.8M | -5.0x | --- |
Tenaya Therapeutics Inc | 338.4M | -2.6x | --- |
Solid Biosciences Inc | 339.1M | -1.9x | --- |
Q32 Bio Inc | 334.3M | -0.8x | --- |
Company Information
FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.
Contact Information
- Headquarters
- 455 E. Medical Center Blvd, Suite 300HOUSTON, TX, United States 77598
- Phone
- 281-671-5152
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer, Founder
- Pete Oheeron
- Chief Financial Officer
- Mark Andersen
- Chief Scientific Officer
- Hamid Khoja
- Independent Director
- Richard Cilento
- Independent Director
- Stacy Coen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $330.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.91 |
Book Value | $0.04 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
